A new study published by the University of Connecticut in the latest issue of Current Pharmaceutical Design shows that daily use of the telomerase activator TA-65® provided protective effects against metabolic abnormalities associated with Metabolic Syndrome.
First randomized, double-blind, placebo controlled study to show telomeres getting longer in humans
This study summarizes the findings on telomere length (TL) changes from a randomized, double blind, placebo controlled study of TA-65 over a 1 year period. The study was conducted on 97 relatively healthy cytomegalovirus-positive subjects aged 53-87 years old.
Functional Assessment of Pharmacological Telomerase Activators in Human T Cells
This human study demonstrates that TA-65MD® nutritional supplements increase telomerase activity and proliferation in human CD4 and CD8 T cells. It highlights the importance of Telomerase Activation in relation to age-associated pathologies.
The Telomerase Activator, TA-65®, Elongates Short Telomeres and Increases Healthspan of Adult/Old Mice without Increasing Cancer Incidence
This animal study looked at the effects of TA-65® and confirmed their mechanism of action, long-term effects, and safety.
Genetic Epidemiology Research on Adult Health and Aging (GERA) Study
In the largest and most diverse study of aging to date, telomere length is being analyzed as a marker for age-related conditions. This genomic project, Genetic Epidemiology Research on Adult Health and Aging (GERA), aims to increase understanding of the genetic basis for a host of problems.
The First Documented Age Reversal in a Mammal: Harvard University Study shows Telomerase Activation Helps Reverse the Aging Process
According to a study published in the January 2011 issue of Nature journal, premature aging can be reversed by reactivating telomerase, the enzyme that lengthens telomeres.